Kenneth I. Moch President, Chief Executive Officer and Director
Kenneth Moch joined Chimerix in 2009 as Chief Operating Officer and was named President and Chief Executive Officer (CEO) in April 2010. He has more than 30 years’ experience in the biomedical arena and has participated in building several companies. Previously, Mr. Moch founded Euclidean Life Science Advisors, a provider of strategic advisory services, where he was most recently President and CEO of BioMedical Enterprises, Inc. He served as Managing Director, Healthcare Investment Banking, at ThinkEquity Partners and as President and CEO of Alteon, Inc., a company specializing in small molecule therapeutics. As President and CEO of Biocyte Corporation, he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell bank. Additionally, Mr. Moch was a co-founder of The Liposome Company, Inc. and a management consultant with McKinsey & Company. Ken currently serves on the Board of the Biotechnology Industry Organization and is a past Chairman of BioNJ. He is a member of the Board of Directors of M2Gen, a for-profit wholly owned subsidiary of the H. Lee Moffitt Cancer & Research Institute. Mr. Moch holds an AB in biochemistry from Princeton University and an MBA from Stanford University.
Timothy W. Trost, CPA Senior Vice President, Chief Financial Officer and Corporate Secretary
Timothy Trost joined Chimerix in 2011 as Senior Vice President and Chief Financial Officer, and had been working with Chimerix since 2010 in a consulting capacity related to the Series F financing and the BARDA contract. With more than 30 years of experience in the financial field, Mr. Trost last served as Vice President and CFO at Argos Therapeutics, Inc., a venture-backed immunotherapy company located in Research Triangle Park. Previously, he was Senior Vice President and CFO at InteCardia, Inc., a venture-backed cardiac imaging company. While at InteCardia, Mr. Trost played a key role in negotiating and executing the sale of the company to Syncor International Corporation (NASDAQ: SCOR). Prior to InteCardia, Mr. Trost served as Executive Vice President and CFO of Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency room physicians, having joined the company as Vice President of Corporate Development. Previously, he held the position of Vice President of Finance at Morganite North America. Mr. Trost began his professional career with PricewaterhouseCoopers LLP, spending time in four offices over 12 years, including an international assignment, and last served as a Senior Manager in the Research Triangle practice. Mr. Trost holds a BS in Accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
M. Michelle Berrey, MD, MPH Chief Medical Officer
Dr. M. Michelle Berrey joined Chimerix in 2012 as Chief Medical Officer. Prior to joining Chimerix, Dr. Berrey was Chief Medical Officer at Pharmasset, Inc. (NASDAQ: VRUS), a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 2007 until its acquisition by Gilead Sciences, Inc. (NASDAQ: GILD) in January 2012. Dr. Berrey's expertise includes the design, early development, medical governance, clinical strategy and product life cycle management of antiviral compounds. Previously, Dr. Berrey served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey received her MD from the Medical College of Georgia and a Master of Public Health from Emory University. She completed her internship and residency in Internal Medicine at the University of North Carolina at Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection. She is Board Certified in Internal Medicine and Infectious Diseases.
Ms. Linda M. Richardson Chief Commercial Officer
Ms. Richardson has over 25 years of pharmaceutical industry experience, with a strong background in launching new products and developing new therapeutic areas. Her category experience includes work in diabetes, anaphylaxis, cardiovascular, respiratory, lipids and neurology. In January 2014, she joined Chimerix, Inc. as Chief Commercial Officer, in charge of building and leading the organization’s commercial structure. Prior to that, Ms. Richardson was the Vice President and Head of the Global lixisenatide franchise, leading the commercial worldwide launch of Lyxumia. She also held the position of Vice President of Marketing at Reliant Pharmaceuticals, overseeing marketing and market research functions, including the successful launch of the first prescription omega-3 product, which helped lead to the company's acquisition by GlaxoSmithKline. Ms. Richardson held various positions of increasing responsibility at GlaxoSmithKline in the sales, market research, and marketing functions, working on several launches. Ms. Richardson served on the Board of Directors of Healthy Women, a non-profit organization dedicated to promoting health and wellness among women. In 2008, she was nominated by her peers as one of the "100 Most Inspiring Leaders" in the Life Sciences field and labeled as a "Market Maker" in PharmaVoice magazine, and in 2011 she was given the "Rising Star" award by the Healthcare Businesswomen's Association. She earned her BA in English at the University of Pennsylvania.
Michael D. Rogers, PhD Chief Development Officer
Dr. Rogers joined Chimerix in 2013 as Chief Development Officer. From 2007 to 2012, Dr. Rogers served as Chief Development Officer at Pharmasset, Inc. (NASDAQ: VRUS), where his primary responsibility was to facilitate the design and implementation of development programs for hepatitis C antiviral compounds. From 2004 to 2007, Dr. Rogers served as Vice President, Division of Viral Diseases at GlaxoSmithKline, where he was responsible for antiviral discovery activities directed toward HIV and hepatitis C indications. From 2001 to 2004, Dr. Rogers served as Vice President, Antiviral Discovery Medicine at GlaxoSmithKline. Dr. Rogers has over 29 years of industry experience and has participated in all phases of antiviral and anti-infective drug development, including discovery, preclinical development, and Phase 1, 2, 3, and 3b/4 clinical development programs. Dr. Rogers received his PhD in medical parasitology and a Master of Public Health in medical microbiology from the University of North Carolina at Chapel Hill. He completed a postdoctoral fellowship in clinical microbiology at St. Jude Children’s Research Hospital in Memphis, Tennessee.
Hervé Momméja-Marin, MD Vice President, Clinical Research
With over 20 years of global medical and clinical research experience in infectious and respiratory disease and clinical medicine, Dr. Momméja-Marin joined Chimerix as Vice President, Clinical Research in 2010. Most recently, he was Senior Medical Director, Infectious Diseases, for i3 Research Limited, a contract research organization, where he was the lead therapeutic expert in infectious diseases. His background includes numerous Phase 1 through Phase 4 clinical trials, including more than 25 late-stage trials, and interactions with regulatory Agencies worldwide. Previously, Dr. Momméja-Marin was Director of Clinical Research for Gilead Sciences, Inc., where he was responsible for the global development of hepatitis B and hepatitis C programs. He also held the positions of Clinical Research Physician at Triangle Pharmaceuticals and Physician of Internal Medicine and Infectious Diseases at Assistance Publique- Hôpitaux de Paris in France. Dr. Momméja-Marin received a medical degree from Paris VII University, France. He is certified in internal medicine and multiple subspecialties.